Onconova Therapeutics Inc. Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients With High-risk Myelodysplastic Syndromes
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEWTOWN, Pa.--(BUSINESS WIRE)--Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, announced it has reached its enrollment goal of 270 for its pivotal Phase 3 ONTIME trial of rigosertib in patients with myelodysplastic syndromes (MDS) who have failed prior therapy with hypomethylating agents.
Help employers find you! Check out all the jobs and post your resume.
NEWTOWN, Pa.--(BUSINESS WIRE)--Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, announced it has reached its enrollment goal of 270 for its pivotal Phase 3 ONTIME trial of rigosertib in patients with myelodysplastic syndromes (MDS) who have failed prior therapy with hypomethylating agents.
Help employers find you! Check out all the jobs and post your resume.